Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Fineline Cube Apr 28, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Drug

China Resources Double-Crane Announces NMPA Clinical Approval for J002 Dry Eye Syndrome Treatment

Fineline Cube Jul 3, 2025

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced that it has received clinical trial...

Company Deals

Sun-Novo Pharma Collaborates with LeKuang Huilin on STC007 for Post-Abdominal Surgery Pain

Fineline Cube Jul 3, 2025

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) this week entered into a technology...

Company Drug

AbbVie’s Venclexta Approved by China’s NMPA for CLL/SLL Patients with 17p Deletion

Fineline Cube Jul 3, 2025

US-based major AbbVie Inc., (NYSE: ABBV) announced that it has received marketing approval from China’s...

Company Drug

Changchun GeneScience’s Firsekibart Receives NMPA Approval for Acute Gouty Arthritis

Fineline Cube Jul 3, 2025

China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received market approval for its...

Company Deals

XtalPi Completes Pre-Seed Investment in Foundry BioSciences to Advance AI-Driven Longevity Therapeutics

Fineline Cube Jul 3, 2025

Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., announced the completion of a...

Company Drug

CANbridge’s Geruining Approved for Gaucher Disease Treatment: First Domestically Developed ERT

Fineline Cube Jul 3, 2025

China-based CANbridge Pharmaceuticals Inc., (HKG: 1228) announced that the first prescription of its Geruining (velaglucerase...

Company Drug

InnoCare Pharma Receives NMPA Clinical Approval for Innovative ADC B7-H3

Fineline Cube Jul 3, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical approval...

Company Drug

Anhui Anke Biotechnology Receives NMPA Clearance for AK2024 in HER2 Positive Solid Tumors

Fineline Cube Jul 2, 2025

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that it has received clinical...

Company Drug

Chengdu Kanghong Receives NMPA Approval for Clinical Trials of KH813 in Metastatic nsq-NSCLC

Fineline Cube Jul 2, 2025

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) announced that it has received clinical...

Company Drug

Takeda Pharmaceutical Gains FDA Approval for Gammagard Liquid Erc in Primary Immunodeficiency

Fineline Cube Jul 2, 2025

Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced that it has received marketing approval from...

Company Deals

3SBio Partners with Thermo Fisher to Advance Cell and Gene Therapy Solutions

Fineline Cube Jul 2, 2025

China-based 3SBio Inc. (HKG: 1530) announced last week a strategic partnership with US-based life sciences...

Company Drug

Jacobio Pharma Initiates First Patient Dosing in U.S. Phase I/IIa Study for Pan-KRAS Inhibitor JAB-23E73

Fineline Cube Jul 2, 2025

China-based Jacobio Pharma (HKG: 1167) announced the first patient dosing of a Phase I/IIa study...

Company Deals Digital

Shanghai Pharmaceuticals’ MediTrust Health Files for IPO in Hong Kong Amidst AI-Powered Healthcare Payment Transformation

Fineline Cube Jul 2, 2025

Shanghai Pharmaceuticals Holding Co., Ltd’s (SPH, HKG: 2607, SHA: 601607) subsidiary, Shanghai MediTrust Health Technology...

Company Drug

Hisun Pharmaceuticals Receives NMPA Approval for HS387 Clinical Trials in Advanced Solid Tumors

Fineline Cube Jul 2, 2025

China-based Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267) announced that it has received clinical trial...

Company Medical Device

China Isotope & Radiation Corporation Showcases C-14 Barium Carbonate at International Symposium

Fineline Cube Jul 2, 2025

China Isotope & Radiation Corporation (CIRC; HKG: 1763) announced that it showcased its C-14 barium...

Company Deals

Merck KGaA Completes $3.4 Billion Acquisition of SpringWorks Therapeutics Boosting Rare Oncology Portfolio

Fineline Cube Jul 2, 2025

German pharmaceutical giant Merck KGaA (ETR: MRK) has completed its USD 3.4 billion (EUR 3...

Company Drug

Allergan Aesthetics’ SKINVIVE by JUVÉDERM Accepted for FDA Review to Reduce Neck Lines

Fineline Cube Jul 2, 2025

Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced that the supplemental premarket approval (sPMA) application...

Company Deals

Hybio and iCarbonX Enter CRDMO Service Pact and Strategic Investment to Advance Peptide Drug Pipeline

Fineline Cube Jul 2, 2025

This week, China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) and iCarbonX entered into an innovative...

Company Deals

EnChannel Medical Acquires AcQMap Platform Assets from Acutus Medical to Strengthen Non-Contact Mapping Tech

Fineline Cube Jul 2, 2025

Guangzhou-based electrophysiology platform company EnChannel Medical Ltd. is set to acquire the AcQMap High Resolution...

Company Deals

Jiangsu Hengrui Pharmaceuticals Partners with NSFC to Establish Private Enterprise Innovation Fund

Fineline Cube Jul 2, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced an agreement with the National...

Posts pagination

1 … 125 126 127 … 658

Recent updates

  • Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication
  • Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A
  • WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion
  • Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization
  • Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication

Others

Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A

Company

WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.